Cediranib

Drug Profile

Cediranib

Alternative Names: AZD-2171; Cediranib-maleate; Recentin; Zemfirza

Latest Information Update: 15 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cancer Research UK; Institute of Cancer Research; National Cancer Institute (Canada); National Cancer Institute (USA); Royal Marsden NHS Foundation Trust; University Health Network; University of Oxford
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Alveolar soft part sarcoma; Prostate cancer; Solid tumours
  • Discontinued Acute myeloid leukaemia; Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 06 Jul 2017 AstraZeneca announces intention to submit NDA to US FDA for Ovarian cancer (Combination therapy, Second-line therapy or greater, Recurrent) in 2020 (AstraZeneca pipeline, July 2017)
  • 02 Jun 2017 Efficacy data from the phase III ICON6 trial in Ovarian Cancer presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Interim efficacy and safety data from a phase II trial in Alveolar soft part sarcoma (In adolescents, In adults, In the elderly, Metastatic disease) presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top